AT-1413
Based on 1 Customer Validation
AT-1413 is a monoclonal antibody targeting CD43s that recognizes a unique sialylated CD43 epitope spanning amino acid residues 133-165. AT1413 induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in AML cells, with EC50 values of 1.1 nM and 12.4 nM, respectively. AT-1413 binds to a variety of cancer cells, shows weak binding to non-malignant myeloid cells and endothelial cells, and does not bind to healthy lymphoid cells or normal non-hematopoietic cells. AT1413 clears CD43s-expressing leukemic blasts in vivo without affecting non-malignant myeloid cells. AT-1413 can be used in research related to acute myeloid leukemia, myelodysplastic syndrome, melanoma, and breast cancer.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 97.60%
-
Speicherung:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
CD43
In Vitro
AT-1413 (10 µg/mL) binds to CD43s in 72% of melanoma tissue samples, but does not bind to adjacent healthy skin cells, as detected by immunohistochemistry[1].
AT-1413 (3 h) recognizes the sialylated epitope of CD43 (CD43s) on the 136.2 and A375 melanoma cell lines[1].
AT1413 (0.001-20 μg/mL) potently induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in SH2-type AML cells in vitro, with EC50 values of 1.1 nM and 12.4 nM, respectively, but does not induce cytotoxicity in non-malignant HAEC, HUVEC or healthy granulocytes[2].
AT1413 specifically binds to CD43s on the surface of AML/MDS blasts, human AML cell lines, and mouse WEHI-3b AML cells, while it shows weak binding to some non-malignant myeloid cells and endothelial cells, and no binding to healthy lymphoid cells or non-hematopoietic cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
AT-1413 (15 mg/kg; i.v.; biweekly) potently eliminates human AML blasts in humanized NSG mice without affecting nonmalignant human myeloid cells[2].
AT-1413 (15 mg/kg; i.v.; biweekly) reduces AML tumor growth in nonhumanized NSG mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NSG mice (NOD.Cg- PrkdcscidIl2rgtm1Wjl/SzJ) (female newborn, human immune system reconstituted, sublethally irradiated, inoculated with human AML cell line SH2 cells)[2]
-
Dosage:15 mg/kg
-
Administration:i.v.; biweekly; starting day 19 after AML cell inoculation
-
Result:Strongly inhibited AML tumor growth via whole-body bioluminescence measurement.
Eliminated AML infiltration in bone, liver, gut, lung, and spleen.
Maintained similar proportions of nonmalignant human CD45+ cells (including T cells, B cells, NK cells, and granulocytes) compared to control antibody-treated mice.
Caused only transient reduced food intake and weight loss after the first injection, with no other significant adverse effects.
-
Animal Model:NSG mice (NOD.Cg- PrkdcscidIl2rgtm1Wjl/SzJ) (nonhumanized, inoculated with luciferase-labeled human AML cell line SH2 cells)[2]
-
Dosage:15 mg/kg
-
Administration:i.v.; biweekly
-
Result:Demonstrated efficacy against luciferase-labeled SH2 AML cells.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Anwendung
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow cytometric analysis of 1X106 THP-1 cells labeling CD43s with AT-1413 (HY-P991425, red). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. AF488-conjugated Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
Appearance Liquid
-
Color Colorless to light yellow
-
SMILES
[AT-1413]
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
-
Data Sheet (279 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
[1]. de Jong G, et al. Melanoma cells can be eliminated by sialylated CD43 × CD3 bispecific T cell engager formats in vitro and in vivo. Cancer immunology, immunotherapy : CII. 2021 Jun;70(6):1569-1581. [Content Brief]
[2]. Gillissen MA, et al. Patient-derived antibody recognizes a unique CD43 epitope expressed on all AML and has antileukemia activity in mice. Blood advances. 2017 Aug 22;1(19):1551-1564. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)